Advances in Targeted Drugs for Adult Acute Myeloid Leukemia

Abstract

Acute myeloid leukemia (AML) is the most common leukemia in adults, characterized by poor prognosis, short survival, high heterogeneity and significant cytogenetic characteristics. In recent years, with the development of molecular targeting and cell biology, many new methods have ap-peared on the basis of traditional chemotherapy for the treatment of this disease. This review fo-cuses on molecular targeted drug therapies targeting disease-specific cytogenetics and recurrent gene changes (e.g., FLT3 inhibitors, IDH inhibitors, BCL-2 inhibitors, Hedgehog pathway inhibitors, etc.), emerging immunotherapies (e.g., CAR T cell therapy). It is expected to further expand treat-ment options for AML and improve patient survival.